Key takeaways: The phase 3 ECZTRA 6 trial evaluated tralokinumab in adolescent atopic dermatitis. One-third of patients reached IGA score of 0 or 1 while more than half reached EASI 75 at 52 weeks.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD ...

More information: Lawrence F. Eichenfield et al, Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized ...

AMSTERDAM — The monoclonal antibody nemolizumab offers long-term efficacy and safety, as well as quality-of-life benefits, in the management of adolescents and adults with moderate to severe ...

Ferrucci SM, Calzavara-Pinton P, Karlova I, et al. Physician-assessed effectiveness and safety in adolescent and adult atopic dermatitis patients treated with dupilumab: real-world insights one ...

Eli Lilly and Almirall’s Ebglyss (lebrikizumab) has been shown to significantly improve the signs and symptoms of atopic ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Thermo Fisher Scientific TMO announced the launch of the international CorEvitas Adolescent Atopic Dermatitis (AD) Registry, designed to study novel treatments for the most common inflammatory ...

Dupixent ® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years Detailed data to be presented at the Revolutionizing Atopic Dermatitis ...

Eichenfield LF, Shi VY, Yu J, et al. Patient-reported impact of atopic dermatitis on pediatric and adolescent patients with moderate-to-severe disease: results of a real-world, cross-sectional survey.

Medical Journeys > Atopic Dermatitis For Your Patients: Atopic Dermatitis 101 — Here's what you need to know about this common skin disease. by Kristin Jenkins, Contributing Writer, MedPage Today ...

Adolescents with atopic dermatitis were also more likely than those without atopic dermatitis to experience bullying at a higher frequency (adjusted odds ratio, 1.97; 95% CI, 1.44–2.68) after ...